Posted On: 09/30/2014 8:51:55 PM
Post# of 273351
Agios Pharmaceuticals Inc (AGIO) 61.35 $AGIO
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
Critical Alerts For Invensense, Agios Pharmaceuticals, SPDR Gold Trust, Nu Skin Enterprises and Nike Released By InvestorsObserver
PR Newswire - Mon Sep 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INVN, AGIO, GLD, NUS and NKE.
Market Maker Surveillance Report. SKY, JNS, CNET, DGLY, AGIO, SFS, Winning Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Skyline Corp (NYSE:SKY), Janus Capital Group Inc (NYSE:JNS), Chinanet Online Holdings Inc (NASDAQ:CNET), Digital Ally Inc (NASDAQ
GLY), (NASDAQ:AGIO), (NYSE:SFS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
'Fast Money' Recap: Why Volatility Might Be a Good Thing
at The Street - Sat Sep 27, 4:00AM CDT
The trading panel discussed how to trade Yahoo!, Nike and biotech companies.
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Sep 26, 7:14PM CDT
Cramer will be looking for more opportunities, especially ones made better by any additional volatility.
Agios drug data boosts stock
at Investor's Business Daily - Fri Sep 26, 5:52PM CDT
Biotech startup Agios Pharmaceuticals (AGIO) got a 19.3% boost to a new high of 63.76 after the company said that it would release key clinical trial data from its phase 1 study of blood cancer treatment AG-120 earlier than anticipated. It's...
Agios' Early Drug-Trial Report Cheers Wall Street
at Investor's Business Daily - Fri Sep 26, 12:21PM CDT
Shares of biotech startup Agios Pharmaceuticals (AGIO) soared 20% in the stock market today to a new high above 64 after it said it would report data from a key clinical trial earlier than expected, leading analysts to believe the news will be good....
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 26, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Jim Cramer's Stop Trading: Does Agios Pharmaceuticals Have a Monumental Cancer Treatment?
at The Street - Fri Sep 26, 10:58AM CDT
TheStreet's Jim Cramer suggests that the only reason Agios Pharmaceuticals would present its cancer treatment data so early is if the company believes it can be monumental in the future.
Agios (AGIO) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 9:12AM CDT
Agios (AGIO) is in Overbought Territory: What’s Next?
Agios Pharmaceuticals (AGIO) Gains: Stock Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 7:44AM CDT
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise 6.4% on the day.
Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014
Business Wire - Fri Sep 26, 6:30AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that clinical data from a Phase 1 study of AG-120, an orally available, selective, potent inhibitor of the mutated IDH1 protein, will be highlighted in a late breaking oral presentation at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain.
Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios
at The Street - Fri Sep 26, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Agios Pharmaceuticals to Present at the 2014 Leerink Partners Rare Disease Roundtable
GlobeNewswire - Tue Sep 23, 3:05PM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its presentation at the 2014 Leerink Partners Rare Disease Roundtable on Wednesday, October 1, 2014 at 3:10 p.m. EDT.
Strong On High Relative Volume: Agios Pharmaceuticals (AGIO)
at The Street - Fri Sep 19, 9:04AM CDT
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a strong on high relative volume candidate
Jim Cramer's Top Stock Picks: AGIO AAPL LUV
at The Street - Wed Sep 17, 5:00AM CDT
Cramer says the charts predict a rally soon for Apple stock while Southwest remains his favorite airline.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Agios Pharmaceuticals (AGIO): Today's Weak On High Volume Stock
at The Street - Fri Sep 12, 9:08AM CDT
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate
Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for the treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is a first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies.
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Tue Aug 12, 12:38PM CDT
Levi & Korsinsky, LLP is investigating Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
Critical Alerts For Invensense, Agios Pharmaceuticals, SPDR Gold Trust, Nu Skin Enterprises and Nike Released By InvestorsObserver
PR Newswire - Mon Sep 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INVN, AGIO, GLD, NUS and NKE.
Market Maker Surveillance Report. SKY, JNS, CNET, DGLY, AGIO, SFS, Winning Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Skyline Corp (NYSE:SKY), Janus Capital Group Inc (NYSE:JNS), Chinanet Online Holdings Inc (NASDAQ:CNET), Digital Ally Inc (NASDAQ
GLY), (NASDAQ:AGIO), (NYSE:SFS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . 'Fast Money' Recap: Why Volatility Might Be a Good Thing
at The Street - Sat Sep 27, 4:00AM CDT
The trading panel discussed how to trade Yahoo!, Nike and biotech companies.
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Sep 26, 7:14PM CDT
Cramer will be looking for more opportunities, especially ones made better by any additional volatility.
Agios drug data boosts stock
at Investor's Business Daily - Fri Sep 26, 5:52PM CDT
Biotech startup Agios Pharmaceuticals (AGIO) got a 19.3% boost to a new high of 63.76 after the company said that it would release key clinical trial data from its phase 1 study of blood cancer treatment AG-120 earlier than anticipated. It's...
Agios' Early Drug-Trial Report Cheers Wall Street
at Investor's Business Daily - Fri Sep 26, 12:21PM CDT
Shares of biotech startup Agios Pharmaceuticals (AGIO) soared 20% in the stock market today to a new high above 64 after it said it would report data from a key clinical trial earlier than expected, leading analysts to believe the news will be good....
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 26, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Jim Cramer's Stop Trading: Does Agios Pharmaceuticals Have a Monumental Cancer Treatment?
at The Street - Fri Sep 26, 10:58AM CDT
TheStreet's Jim Cramer suggests that the only reason Agios Pharmaceuticals would present its cancer treatment data so early is if the company believes it can be monumental in the future.
Agios (AGIO) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 9:12AM CDT
Agios (AGIO) is in Overbought Territory: What’s Next?
Agios Pharmaceuticals (AGIO) Gains: Stock Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 7:44AM CDT
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise 6.4% on the day.
Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014
Business Wire - Fri Sep 26, 6:30AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that clinical data from a Phase 1 study of AG-120, an orally available, selective, potent inhibitor of the mutated IDH1 protein, will be highlighted in a late breaking oral presentation at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain.
Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios
at The Street - Fri Sep 26, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Agios Pharmaceuticals to Present at the 2014 Leerink Partners Rare Disease Roundtable
GlobeNewswire - Tue Sep 23, 3:05PM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its presentation at the 2014 Leerink Partners Rare Disease Roundtable on Wednesday, October 1, 2014 at 3:10 p.m. EDT.
Strong On High Relative Volume: Agios Pharmaceuticals (AGIO)
at The Street - Fri Sep 19, 9:04AM CDT
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a strong on high relative volume candidate
Jim Cramer's Top Stock Picks: AGIO AAPL LUV
at The Street - Wed Sep 17, 5:00AM CDT
Cramer says the charts predict a rally soon for Apple stock while Southwest remains his favorite airline.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Agios Pharmaceuticals (AGIO): Today's Weak On High Volume Stock
at The Street - Fri Sep 12, 9:08AM CDT
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate
Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for the treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is a first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies.
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Tue Aug 12, 12:38PM CDT
Levi & Korsinsky, LLP is investigating Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
(0)
(0)
